Question from Deputy Claire Kerrane - PQ 52886-26
Deputy Kerrane asked why Tucatinib (Tukysa) is not accessible to cancer patients in Ireland. Read the HSE response.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy Kerrane asked why Tucatinib (Tukysa) is not accessible to cancer patients in Ireland. Read the HSE response.
Deputy Mitchell asked about the current waiting times for a speech and language therapy at the Killester Health Centre. Read the HSE response.
Deputy Ó Súilleabháin asked about dietitian services in Gorey CDNT. Read the HSE response.
Deputy O'Flynn asked about the establishment of an interim oversight mechanism pending full rollout of MedLIS and the Regional Laboratory Networks.
Deputy Brabazon asked for the number of psychologist posts filled at Clontarf CDNT. Read the HSE response.
Deputy O'Flynn asked about the external review of Children's Health Ireland's operational readiness. Read the HSE response.
Deputy Brady asked about the number of instances where ambulances in Wicklow did not arrive within the targeted timeframe. Read the HSE response.
Deputy Ó Broin asked if skyclarys will be on the agenda for the upcoming HSE Drugs Group meeting in July. Read the HSE response.
Deputy O'Flynn asked if any minutes, file notes, or correspondence concerning the WPATH Standards of Care Version 7 decision exist. Read the HSE response.
Deputy O'Meara asked about the establishment of a Sexual Assault Treatment Unit (SATU) in the mid-west. Read the HSE response.